Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 2/20 | 0.32 |
| ▸ | ARG2 | P78540 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16824000 | 0.87 | HSD17B10 (0.36) | HSD17B10LMNACYP2C19DPP4DPP8 | |
| SCHEMBL771422 | 0.85 | HSD17B10 (0.35) | HSD17B10LMNACYP2C19SMN1; SMN2FKBP1A | |
| SCHEMBL771421 | 0.85 | HSD17B10 (0.35) | HSD17B10LMNACYP2C19SMN1; SMN2FKBP1A | |
| SCHEMBL22371588 | 0.83 | HCRTR2 (0.33) | HSD17B10LMNACYP2C19DPP4SMN1; SMN2 | |
| SCHEMBL22371501 | 0.83 | HCRTR2 (0.33) | HSD17B10LMNACYP2C19DPP4SMN1; SMN2 | |
| SCHEMBL2582264 | 0.83 | HCRTR2 (0.33) | HSD17B10LMNACYP2C19DPP4SMN1; SMN2 | |
| SCHEMBL14678324 | 0.83 | HSD17B10 (0.39) | HSD17B10LMNACYP2C19DPP4DPP8 | |
| SCHEMBL771956 | 0.83 | POLB (0.41) | HSD17B10LMNACYP2C19DPP4DPP8 | |
| SCHEMBL5469615 | 0.83 | POLB (0.41) | HSD17B10LMNACYP2C19DPP4DPP8 | |
| SCHEMBL8646401 | 0.83 | POLB (0.41) | HSD17B10LMNACYP2C19DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | HSD17B10 1073/4885LMNA 4323/4885CYP2C19 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.